Characterizing tumor microenvironment heterogeneity in EBV+ nTNKL vs ENKTL using spatial transcriptomics and MIF

Read full text
Authors: Siyu Qian, ZeYuan Wang, Yue Zhang, Wanyue Zhao, Honghan Qiao, Xiaoyan Feng, Yukai Duan, Boyuan Su, Shifeng Hao, Zhenzhen Yang, Mingzhi Zhang, Qingjiang Chen
+3 more Guannan Wang, Shenglei LI, Xudong Zhang
Cited by: 2
References: 44

Abstract

Background Epstein–Barr virus (EBV)-positive nodal T/NK-cell lymphoma (EBV + nTNKL) has recently been delineated in the WHO-HAEM5 classification as a distinct and exceptionally rare entity. Its biology and clinical trajectory remain obscure relative to Extranodal NK/T-cell lymphoma (ENKTL). Methods We applied spatial transcriptomics and multiplex immunofluorescence to representative ENKTL and EBV + nTNKL specimens, integrating these data with a retrospective clinical cohort of 14 EBV + nTNKL patients—constituting one of the largest series described to date. Results Spatial transcriptomics revealed fundamental differences between ENKTL and EBV + nTNKL. ENKTL, of NK-cell origin, displayed higher malignant cell density, neutrophil enrichment, and an immune-desert phenotype, whereas EBV + nTNKL, of T-cell origin, showed reduced tumor burden, B-cell enrichment, and an immune-active microenvironment with abundant cytotoxic T cells and PD-1/PD-L1 expression. Intercellular communication analyses further highlighted distinct signaling programs—TGF-β/BMP-driven tumor–neutrophil interactions in ENKTL versus CXCL/CCL–GPCR-mediated macrophage crosstalk in EBV + nTNKL. In a retrospective cohort of 14 EBV + nTNKL patients, the disease was frequently complicated by hemophagocytic lymphohistiocytosis and conferred significantly inferior survival, although selected patients achieved durable responses with immune checkpoint inhibitors or CAR-T therapy. Conclusion This study delineates the immunologic and molecular architectures of ENKTL and EBV + nTNKL, providing rare insights into this understudied lymphoma. Despite limited sampling, these findings underscore the central role of EBV latency programs and tissue context in shaping tumor ecology and suggest avenues for subtype-tailored therapeutic strategies.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Immune Cell Function and Interaction Viral-associated cancers and disorders

Publication details

Journal / source
Frontiers in Immunology
Publisher
Frontiers Media SA
Volume
17
Pages
1717844–1717844
Publication date
11 February 2026
Language
EN